Back to Newsroom

Combimatrix’s Pediatric Development Disorders Analysis Test Granted Conditional Approval from New York State Department of Health

IRVINE, California, July 15, 2014 (GLOBE NEWSWIRE) – CombiMatrix Corporation (NASDAQ: CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that its chromosomal microarray analysis (CMA) test to identify development disorders in pediatric patients, the CombiSNP™ Array for Pediatric Analysis, has received conditional approval from the New York Department of Health for testing on patient samples. In 2013, the New York Department of Health granted CombiMatrix approval to market its CombiSNP™ CMA test for miscarriage analysis.

Click here to read more